332 related articles for article (PubMed ID: 25829524)
21. Payer management of oncology gets serious.
Snyder M; Goldberg L; Ryan T
Am J Manag Care; 2012 Feb; 18(1 Spec No.):SP6-7. PubMed ID: 22468875
[No Abstract] [Full Text] [Related]
22. US signs contract with ZMapp maker to accelerate development of the Ebola drug.
McCarthy M
BMJ; 2014 Sep; 349():g5488. PubMed ID: 25189475
[No Abstract] [Full Text] [Related]
23. How can attrition rates be reduced in cancer drug discovery?
Moreno L; Pearson AD
Expert Opin Drug Discov; 2013 Apr; 8(4):363-8. PubMed ID: 23373702
[TBL] [Abstract][Full Text] [Related]
24. The current state of drug discovery and what it might take to improve drug discovery outcomes and approval successes.
Turner MJ
Drug Discov Today; 2015 Aug; 20(8):917-9. PubMed ID: 26100736
[No Abstract] [Full Text] [Related]
25. Is the GAIN Act a turning point in new antibiotic discovery?
Brown ED
Can J Microbiol; 2013 Mar; 59(3):153-6. PubMed ID: 23540332
[TBL] [Abstract][Full Text] [Related]
26. Targeted immunotherapies overtaking emerging oncology market value based growth.
Jakovljevic MB
J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
[No Abstract] [Full Text] [Related]
27. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
[TBL] [Abstract][Full Text] [Related]
28. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
Gitter DM
Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
[No Abstract] [Full Text] [Related]
29. [Earlier value assessment of pharmaceutical products and medical science].
Selbmann HK
Nervenarzt; 2016 Apr; 87(4):353-5. PubMed ID: 27000270
[No Abstract] [Full Text] [Related]
30. Fast-track approval of medicines in Australia.
Nash L
Lancet Oncol; 2016 Nov; 17(11):1487. PubMed ID: 27693239
[No Abstract] [Full Text] [Related]
31. Industry must communicate value and contribution of drugs to Congress and public.
Gatty B
Hosp Formul; 1994 May; 29(5):406, 405. PubMed ID: 10133903
[No Abstract] [Full Text] [Related]
32. Drug safety reform at the FDA--pendulum swing or systematic improvement?
McClellan M
N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
[No Abstract] [Full Text] [Related]
33. Pharmaceuticals and medical devices: cost savings. Issue brief.
Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-33. PubMed ID: 23297446
[No Abstract] [Full Text] [Related]
34. [Healthy pharmaceutical policy].
González Pier E
Salud Publica Mex; 2008; 50 Suppl 4():S488-95. PubMed ID: 19082260
[TBL] [Abstract][Full Text] [Related]
35. Budget cuts in the USA: a short-term win?
Lancet Oncol; 2012 Jan; 13(1):1. PubMed ID: 22225713
[No Abstract] [Full Text] [Related]
36. Cancer research: does it deliver for the patient?
Oldham RK
Cancer Biother; 1994; 9(2):99-102. PubMed ID: 7812366
[No Abstract] [Full Text] [Related]
37. [Health policy in coalition agreement. Good effort - but not a great success].
Montgomery FU
MMW Fortschr Med; 2013 Dec; 155(21-22):16. PubMed ID: 24724255
[No Abstract] [Full Text] [Related]
38. The GAIN Act legislation to combat antimicrobial resistance: Where do we stand?
Sfeir MM
Infect Control Hosp Epidemiol; 2018 Dec; 39(12):1499-1500. PubMed ID: 30334503
[No Abstract] [Full Text] [Related]
39. Oncology payment reform to achieve real health care reform.
McClellan MB; Thoumi AI
J Oncol Pract; 2015 May; 11(3):223-30. PubMed ID: 25901049
[TBL] [Abstract][Full Text] [Related]
40. We Can use Market Forces to Moderate Drug Prices.
Miller HI
Mo Med; 2019; 116(6):451-453. PubMed ID: 31911716
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
